DUBLIN, IRELAND--(MARKET WIRE)--Jun 23, 2008 -- Trinity Biotech plc (NasdaqGS:TRIB - News), a leading developer and manufacturer of diagnostic products for the point-of-care and clinical laboratory markets, today announced that it will demonstrate its new Destiny Max instrument at the MLTD (Mediterranean League against Thromboembolic Diseases) conference in Athens, Greece from June 25th to 28th.
